Vaxart Q2 Earnings Call Highlights
Source: MarketBeat· MarketBeat· August 9, 2026
SynaBot summary
Vaxart announced positive 12-month safety results from its Phase II-B COVID-19 vaccine study. The Sentinel cohort, comprising 400 participants, showed no significant adverse events over the extended observation period.
Key takeaways
- 12-month safety data from Phase II-B trial released
- 400-participant Sentinel cohort showed positive results
- No significant safety concerns identified over a year
Why it matters
This long-term safety data is crucial for AI developers working on healthcare applications. It provides evidence of vaccine stability and patient well-being, informing the development of AI tools for clinical trial analysis and patient monitoring.
This story was reported by MarketBeat. Read the full original article:
Read on MarketBeat Try this on SynaBot
Related AI assistants, prompts, and tools from the SynaBot catalog.
AI Prompts
AI Tools
- RecallRecall is an AI video tool that helps users summarize and repurpose long-form video content into short-form clips, scripts, storyboards, and captions.
- KrispCallKrispCall is a cloud telephony system that integrates AI for intelligent call management features. It offers call recording, analytics, and virtual numbers, enhancing communication for businesses of all sizes.
- Call AnnieCall Annie provides an AI-powered virtual assistant chatbot for businesses to build conversational experiences, automate frequently asked questions, and offer guided support to their users or internal teams.
